What does survodutide do?

Most GLP-1 drugs (like semaglutide in Ozempic) work by activating one receptor — GLP-1. This slows your stomach, reduces appetite, and helps with blood sugar. Survodutide does all of that plus activates glucagon receptors.

Why does that matter? Glucagon tells your liver to burn stored fat for energy. This dual action gives you two benefits at once: appetite suppression (GLP-1) and increased fat burning, particularly in the liver (glucagon). In trials, this combination produced about 19% body weight loss over 46 weeks.

Who is it for?

• People with obesity and fatty liver — the dual mechanism directly targets both problems
• Those who haven't responded enough to GLP-1-only drugs — the added glucagon action may push results further
• People with MASH (metabolic-associated steatohepatitis) — survodutide is specifically being tested for this condition

Since it's not yet approved, it's not currently available for anyone outside clinical trials.

How it's taken

India context

Survodutide is not available in India and won't be for several years. Here's what you should know:

• Fatty liver prevalence: India has one of the highest rates of non-alcoholic fatty liver disease globally — estimated at 30–40% of the adult population. A drug that specifically targets liver fat would be significant here.
• Timeline: Boehringer Ingelheim is running Phase 3 trials (the SYNCHRONIZE program). Even if approved by the FDA, Indian availability would likely follow 1–2 years later — realistically 2028–2029 at the earliest.
• No generics yet: Unlike semaglutide which now has Indian generics, survodutide patents won't expire for many years. Expect high costs initially.

Frequently Asked Questions

How it works in your body

Survodutide is a peptide that binds to two different receptors. The GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion — the same mechanism behind Ozempic and Mounjaro. The glucagon receptor activation is the novel part.

When glucagon receptors in your liver are activated, your liver ramps up fatty acid oxidation — essentially burning its own fat stores for energy. This also increases whole-body energy expenditure. The net effect: you eat less (GLP-1) while burning more (glucagon), and your liver specifically sheds stored fat.

What the trials show

• SYNCHRONIZE-1 (obesity): ~19% body weight reduction at 46 weeks with the highest dose (6.0 mg). Placebo lost about 2%.
• SYNCHRONIZE-4 (MASH): Significant reduction in liver fat content and improvement in liver fibrosis markers — a first for this drug class.
• Compared to semaglutide: Direct head-to-head data is limited, but the ~19% weight loss is in the range of semaglutide (15–17%) with potentially better liver outcomes.
• Heart rate: A small but consistent increase in resting heart rate was observed (2–4 bpm), likely from the glucagon component.

Side effects & safety

The side effect profile is similar to other GLP-1 drugs, with the GI symptoms being most prominent during dose escalation:

• Nausea — the most common side effect, affecting 30–40% of participants. Usually subsides after the first few weeks at each dose level.
• Vomiting — reported in about 10–15% of participants. More common during dose increases.
• Diarrhea — affects roughly 15–20%. Generally mild and self-limiting.
• Decreased appetite — expected and partly how the drug works, but can be excessive in some people.
• Heart rate increase — a mild elevation of 2–4 bpm has been observed, likely from glucagon receptor activation. Being monitored closely in ongoing trials.
• Injection site reactions — occasional redness or mild pain at the injection site.

Who should be cautious: People with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome, as with all GLP-1 class drugs. Those with significant heart rhythm issues should discuss the heart rate effect with their doctor.

Which labs to check

If survodutide becomes available and you're considering it, baseline and follow-up labs should include:

• Liver enzymes (ALT, AST, GGT) — to track liver fat improvement
• FibroScan or ultrasound — for liver fat quantification
• HbA1c and fasting insulin — metabolic baseline
• Lipid panel — cholesterol and triglycerides tend to improve
• Heart rate monitoring — given the mild tachycardia signal

Related